Argentum invests in Hadean Ventures

Argentum invests NOK 150 million in the Norwegian life sciences fund Hadean Ventures, together with three of its private investment partners.

Oslo based Hadean Ventures will focus exclusively on venture companies in the life sciences sector.
– Norway spends a lot of money on research and development in the health sector. However, we need people like Ingrid and her team with expertise in commercialization and international growth. I see no reason why Norwegian life science companies should not have international potential, says Joachim Høegh-Krohn, CEO of Argentum.

The new venture capital fund is established by Ingrid Teigland Akay from Norway, Walter Stockinger from Austria and Siro Perez from Spain. The international team will be based in Oslo, Norway. The three partners joined forces after working together in Inventages, a world-leading fund within the life sciences sector.

 

– It is inspiring that investors like Argentum share our confidence in this market. The real effort starts now, namely to develop and grow these companies internationally, says Ingrid Teigland Akay, partner in Hadean Ventures.

Ingrid Teigland Akay is a medical doctor and venture investor with broad experience from the life sciences and technology sector. She previously worked for Invetages, a leading venture capital firm within the life sciences sector. As a medical doctor, she also has broad clinical experience working With general medicine, surgery and internal medicine.

Teigland Akay and her team have several promising companies in their pipeline:
– Norway and the Nordic market is uncharted territory for investments within life sciences. We observe a strong dealflow throughout Norway, not only limited to the larger cities, says Teigland Akay.

Høegh-Krohn, CEO of Argentum, shares Teigland Akay’s perspective:
– We invest in Hadean Ventures because we believe in the health sectors growth potential, and in Hadean Venture’s ability to locate and develop companies that solves the problems of tomorrow.

About the team
Ingrid Teigland Akay is a medical doctor and experienced investment professional. Ingrid previously worked at Invetages, one of the world’s largest life science focused venture funds, where she invested in and supported start-up companies in Europe, the U.S. and China. She has broad clinical experience within fields such as general medicine, surgery and internal medicine, and she has worked in both the public and private sector in several European countries including Scandinavia, Germany and the UK. Ingrid holds a medical degree from Medizinische Hochschule in Hannover, Germany, and an MBA from London Business School.

Walter Stockinger is a seasoned healthcare investor with experience from research and strategy consulting. He has a background from Inventages, where he invested in and supported start-up companies, from Boston Consulting Group, where he was at the Healthcare Practice Team, and as a scientist at Harvard University. Walter holds an MSc in Chemistry and a PhD in Biochemistry from the University of Vienna.

Siro Perez is a serial entrepreneur and has co-founded and held CEO roles in several start-ups within the life sciences field, among them the e-health company Molecular Warehouse. He started his career in Novartis, and has experience from Inventages and Boston Consulting Group. Siro holds a Masters in Finance from LBS, a PhD summa cum laude in Molecular Biology and an MSc in Chemistry from the Autonoma University of Madrid. He has also studied Computer Science Engineering at UNED.